Tag: T-Cell Immunotherapies

Cancer is one of the leading causes of mortality, accounting for 0.6 million deaths in 2021, in the US alone. As per the International Agency for Research on Cancer (IARC), by 2040, there are likely to be 27.5 million new cases and 16.3 million deaths related to cancer, annually. Although cancer therapeutics continue to be

T-Cell immunotherapies have gained a lot of traction in recent years. With a plethora of clinical evidence and billions of dollars in investment, calling T-cell therapies as the next big thing might not be incorrect. As per the recent estimates, this space is likely to grow to USD 26 billion by 2030, at a CAGR

The cancer therapeutics market is considered to be one of the most active segments within the pharmaceutical industry. In the past five years, the USFDA has approved more than 100 drugs for the treatment of different types of cancer. According to the International Agency for Research on Cancer (IARC), close to 17 million new cases

Amidst the current initiatives to develop more targeted anti-cancer therapies, immunotherapy has emerged as a highly potent option to eradicate tumor cells with minimal side effects. It is based on the principle of harnessing the innate potential of the immune system to target and destroy diseased cells. It encompasses several treatment approaches, such as monoclonal